Calidi Biotherapeutics, Inc. (CLDI)
CLDIAMEXBiotechnology: Biological Products (No Diagnostic Substances)
$0.6224
-0.0323 (-4.93%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $2.30m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6200 to $24.96
- Average volume
- –
- Previous close
- $0.6547
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$5.05m | -$4.47m | -$4.19m | -$4.15m |
| Net income | -$5.15m | -$4.06m | -$4.11m | -$4.16m |
News
8 latest- Calidi Put On Notice By NYSE For Non-Compliance In Stockholders' Equity; Shares Fall By 5% RTTNews · Sep 26, 2026
- Calidi Biotherapeutics Unveils $1.2 Mln Offering Of Shares; Stock Up RTTNews · Sep 17, 2026
- Calidi Announces Reverse Stock Split; Shares Tumble 15% In Premarket Trading RTTNews · Jul 21, 2026
- Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of Directors RTTNews · Jun 24, 2026
- Calidi Partners With TransferAI To Streamline IND Submission For Tumor Virotherapy CLD-401 RTTNews · Apr 29, 2026
- Calidi Releases New Data On RedTail Mechanism For Cancer Treatment RTTNews · Apr 21, 2026
- Calidi Partners With Avance Clinical For CLD-401 Trial Initiation In Australia; Stock Up RTTNews · Mar 24, 2026
- Calidi Closes $6 Million Offering To Advance Cancer Immunotherapy Pipeline RTTNews · Mar 10, 2026
The company
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, is being developed for metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.